Toxicity profile of the GATA-3-specific DNAzyme hgd40 after inhalation exposure

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 2, 2013, Pages 281-289

  Fuhst, Rainer ^a   Runge, Frank ^b   Buschmann, Jochen ^a   Ernst, Heinrich ^a   Praechter, Christiane ^b   Hansen, Tanja ^a   von Erichsen, Jasmin ^b   Turowska, Agnieszka ^c   Hoymann, Heinz Gerd ^a   Müller, Meike ^a   Pohlmann, Gerhard ^a   Sewald, Katherina ^a   Ziemann, Christina ^a   Schlüter, Gerhard ^d   Garn, Holger ^c,e  

^a FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^b Nycomed GmbH   (Germany)

^c Biomedical Research Center   (Germany)

^d Institute of Laboratory Medicine and Pathobiochemistry ^*

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Antisense; Asthma; DNAzyme; GATA 3; Safety; Toxicity

Indexed keywords

DEOXYRIBOZYME; GAMMA INTERFERON; HGD 40; INTERLEUKIN 10; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG;

AEROSOL; ARTICLE; ASTHMA; BLOOD; BRONCHUS DISEASE; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOG; DRUG EXPOSURE; DRUG SAFETY; GENOTOXICITY; HISTIOCYTOSIS; HISTOPATHOLOGY; HYPERPLASIA; IMMUNOTOXICITY; LUNG LAVAGE; LYMPHOID TISSUE; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; RAT; RESPIRATORY SYSTEM;

ADMINISTRATION, INHALATION; ANIMALS; BRAIN; BRONCHOALVEOLAR LAVAGE FLUID; DNA, CATALYTIC; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GATA3 TRANSCRIPTION FACTOR; HEART; INTERFERON-GAMMA; INTERLEUKIN-10; LUNG; LYMPHOCYTES; MALE; RATS; RATS, WISTAR;

EID: 84874578588     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2012.12.005     Document Type: Article

References (26)

1. Grimpe B. Deoxyribozymes: new therapeutics to treat central nervous system disorders. Front Mol Neurosci 2011, 4:25.
2. Peer D., Lieberman J. Special delivery: targeted therapy with small RNAs. Gene Ther 2011.
3. Santoro S.W., Joyce G.F. A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci U S A 1997, 94:4262-4266.
4. Santoro S.W., Joyce G.F. Mechanism and utility of an RNA-cleaving DNA enzyme. Biochemistry 1998, 37:13330-13342.
5. Guimond A., Viau E., Aube P., Renzi P.M., Paquet L., Ferrari N. Advantageous toxicity profile of inhaled antisense oligonucleotides following chronic dosing in non-human primates. Pulm Pharmacol Ther 2008, 21:845-854.
6. Sel S., Wegmann M., Dicke T., Henke W., Yildirim A.O., Renz H., et al. Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme. J Allergy Clin Immunol 2008, 121:910 e5-916 e5.
7. Cohn L., Elias J.A., Chupp G.L. Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol 2004, 22:789-815.
8. Larche M., Robinson D.S., Kay A.B. The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol 2003, 111:450-463. quiz 64.
9. Chatila T.A., Li N., Garcia-Lloret M., Kim H.J., Nel A.E. T-cell effector pathways in allergic diseases: transcriptional mechanisms and therapeutic targets. J Allergy Clin Immunol 2008, 121:812-823. quiz 24-5.
10. Cousins D.J., McDonald J., Lee T.H. Therapeutic approaches for control of transcription factors in allergic disease. J Allergy Clin Immunol 2008, 121:803-809. quiz 10-1.
11. Ho I.C., Tai T.S., Pai S.Y. GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation. Nat Rev Immunol 2009, 9:125-135.
12. Zhu J., Yamane H., Cote-Sierra J., Guo L., Paul W.E. GATA-3 promotes Th2 responses through three different mechanisms: induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors. Cell Res 2006, 16:3-10.
13. Finotto S., De Sanctis G.T., Lehr H.A., Herz U., Buerke M., Schipp M., et al. Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J Exp Med 2001, 193:1247-1260.
14. Bide R.W., Armour S.J., Yee E. Allometric respiration/body mass data for animals to be used for estimates of inhalation toxicity to young adult humans. J Appl Toxicol 2000, 20:273-290.
15. Raabe O.G., Al-Bayati M.A., Teague S.V., Rasolt A. Regional deposition of inhaled monodisperse coarse and fine aerosol particles in small laboratory animals. Ann Occup Hyg 1988, 32:53-63.
16. Glaab T., Hoymann H.G., Hohlfeld J.M., Korolewitz R., Hecht M., Alarie Y., et al. Noninvasive measurement of midexpiratory flow indicates bronchoconstriction in allergic rats. J Appl Physiol 2002, 93:1208-1214.
17. Hoymann H.G. Invasive and noninvasive lung function measurements in rodents. J Pharmacol Toxicol Methods 2007, 55:16-26.
18. Gad S.C. A neuromuscular screen for use in industrial toxicology. J Toxicol Environ Health 1982, 9:691-704.
19. Moser V.C., McDaniel K.L., Phillips P.M. Rat strain and stock comparisons using a functional observational battery: baseline values and effects of amitraz. Toxicol Appl Pharmacol 1991, 108:267-283.
20. Meyer O.A., Tilson H.A., Byrd W.C., Riley M.T. A method for the routine assessment of fore- and hindlimb grip strength of rats and mice. Neurobehav Toxicol 1979, 1:233-236.
21. Singh N.P., McCoy M.T., Tice R.R., Schneider E.L. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988, 175:184-191.
22. Tice R.R., Agurell E., Anderson D., Burlinson B., Hartmann A., Kobayashi H., et al. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 2000, 35:206-221.
23. Jason T.L., Koropatnick J., Berg R.W. Toxicology of antisense therapeutics. Toxicol Appl Pharmacol 2004, 201:66-83.
24. Levin A.A. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1999, 1489:69-84.
25. Vollmer J., Jepsen J.S., Uhlmann E., Schetter C., Jurk M., Wader T., et al. Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA). Oligonucleotides 2004, 14:23-31.
26. Chan J.H., Lim S., Wong W.S. Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 2006, 33:533-540.